1218 related articles for article (PubMed ID: 33515606)
1. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J
Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606
[TBL] [Abstract][Full Text] [Related]
2. Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
Scholle MD; O'Kane PT; Dib S; Gurard-Levin ZA
Antiviral Res; 2022 Apr; 200():105279. PubMed ID: 35278580
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
[TBL] [Abstract][Full Text] [Related]
4. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
Cell Res; 2020 Aug; 30(8):678-692. PubMed ID: 32541865
[TBL] [Abstract][Full Text] [Related]
7. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
[TBL] [Abstract][Full Text] [Related]
8. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
[TBL] [Abstract][Full Text] [Related]
9. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
10. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
11. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
[TBL] [Abstract][Full Text] [Related]
12. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.
Ma C; Xia Z; Sacco MD; Hu Y; Townsend JA; Meng X; Choza J; Tan H; Jang J; Gongora MV; Zhang X; Zhang F; Xiang Y; Marty MT; Chen Y; Wang J
J Am Chem Soc; 2021 Dec; 143(49):20697-20709. PubMed ID: 34860011
[TBL] [Abstract][Full Text] [Related]
14. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT
FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393
[TBL] [Abstract][Full Text] [Related]
15. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
16. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
[TBL] [Abstract][Full Text] [Related]
17. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
[TBL] [Abstract][Full Text] [Related]
18. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.
Vandyck K; Deval J
Curr Opin Virol; 2021 Aug; 49():36-40. PubMed ID: 34029993
[TBL] [Abstract][Full Text] [Related]
19. Merbromin is a mixed-type inhibitor of 3-chyomotrypsin like protease of SARS-CoV-2.
Chen J; Zhang Y; Zeng D; Zhang B; Ye X; Zeng Z; Zhang XK; Wang Z; Zhou H
Biochem Biophys Res Commun; 2022 Feb; 591():118-123. PubMed ID: 35007835
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses.
Sharma A; Kaliya K; Maurya SK
Curr Top Med Chem; 2021; 21(4):307-328. PubMed ID: 33183205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
